Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor.To, C., Jang, J., Chen, T., Park, E., Mushajiang, M., De Clercq, D.J.H., Xu, M., Wang, S., Cameron, M.D., Heppner, D.E., Shin, B.H., Gero, T.W., Yang, A., Dahlberg, S.E., Wong, K.K., Eck, M.J., Gray, N.S., Janne, P.A.
(2019) Cancer Discov 9: 926-943
- PubMed: 31092401
- DOI: 10.1158/2159-8290.CD-18-0903
- PubMed Abstract:
Allosteric kinase inhibitors offer a potentially complementary therapeutic strategy to ATP-competitive kinase inhibitors due to their distinct sites of target binding. In the present study, we identify and study a mutant-selective EGFR allosteric inh ...
Allosteric kinase inhibitors offer a potentially complementary therapeutic strategy to ATP-competitive kinase inhibitors due to their distinct sites of target binding. In the present study, we identify and study a mutant-selective EGFR allosteric inhibitor, JBJ-04-125-02, which as a single agent, can inhibit cell proliferation and EGFR L858R/T790M/C797S signaling in vitro and in vivo. However, increased EGFR dimer formation limits treatment efficacy and leads to drug resistance. Remarkably, osimertinib, an ATP-competitive covalent EGFR inhibitor, uniquely and significantly enhances the binding of JBJ-04-125-02 for mutant EGFR. The combination of osimertinib and JBJ-04-125-02 results in an increase in apoptosis, a more effective inhibition of cellular growth, and an increased efficacy in vitro and in vivo compared to either single agent alone. Collectively, our findings suggest that the combination of a covalent mutant-selective ATP-competitive and an allosteric EGFR inhibitor may be an effective therapeutic approach for patients with EGFR-mutant lung cancer.
Medical Oncology, Dana-Farber Cancer Institute email@example.com.,Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute.,Medical Oncology, Dana-Farber Cancer Institute.,Perlmutter Cancer Center, NYU Langone Medical Center.,Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Brigham and Women's Hospital.,Perlmutter Cancer Center, New York University Langone Medical Center.,Cancer Biology, Dana-Farber Cancer Institute.,The Translational Research Institute, The Scripps Research Institute, Scripps Florida.,Dana Farber Cancer Institutue, Department of Radiation Oncology, Harvard Medical School.,Department of Cancer Biology, Dana-Farber Cancer Institute.